Listed

Arcus Biosciences, Inc.

RCUSNYSECIK 1724521HealthcareFiscal year ends Dec 31

Latest reported revenue, Q2 FY2026$33.0mRevenue, Q2 FY2026, three months to 2026-06-30$33.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-05, accession 0001724521-26-000044.Report this figureThree months to Jun 30, 2026, from the 10-Q filed Aug 5, 2026.

Latest quarter: Q2 FY2026

Three months to Jun 30, 2026, against the same quarter a year earlier.

  • Revenue$33.0mRevenue, Q2 FY2026, three months to 2026-06-30$33.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-05, accession 0001724521-26-000044.Report this figure+312.5% on a year earlier
  • Gross marginnot reported (Gross profit not reported)No year-earlier figure to compare
  • Operating margin−290.9%Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: −$96.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-05, accession 0001724521-26-000044.Revenue: $33.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-05, accession 0001724521-26-000044.Report this figure−190.9 pts on a year earlier
  • Net margin−275.8%Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: −$91.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-05, accession 0001724521-26-000044.Revenue: $33.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-05, accession 0001724521-26-000044.Report this figure−275.8 pts on a year earlier
  • Diluted EPS−$0.72Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.72 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-05, accession 0001724521-26-000044.Report this figureSign changed from a year earlier
  • Free cash flow−$119.0mFree cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: −$119.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-05, accession 0001724521-26-000044. Derived: 6-month figure less the 3-month figure.Capital expenditure: $0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-05, accession 0001724521-26-000044. Derived: 6-month figure less the 3-month figure.Report this figure+10.5% on a year earlier

Last eight quarters

Full statements
Revenue$33.0mOperating margin −290.9%
Diluted EPS−$0.72, Q2 FY2026
Free cash flow−$119.0m, Q2 FY2026
Arcus Biosciences, Inc., key figures for the last eight quarters
Line itemUnitQ3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30Shape over the periods
Revenue$m7.0Revenue, Q3 FY2024, three months to 2024-09-30$7.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-10-28, accession 0001724521-25-000116.Report this figure23.0Revenue, Q4 FY2024, three months to 2024-12-31$23.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-25, accession 0001724521-26-000009. Derived: 12-month figure less the 9-month figure.Report this figure8.0Revenue, Q1 FY2025, three months to 2025-03-31$8.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-05, accession 0001724521-26-000034.Report this figure8.0Revenue, Q2 FY2025, three months to 2025-06-30$8.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-05, accession 0001724521-26-000044.Report this figure6.0Revenue, Q3 FY2025, three months to 2025-09-30$6.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-10-28, accession 0001724521-25-000116.Report this figure11.0Revenue, Q4 FY2025, three months to 2025-12-31$11.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-25, accession 0001724521-26-000009. Derived: 12-month figure less the 9-month figure.Report this figure7.0Revenue, Q1 FY2026, three months to 2026-03-31$7.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-05, accession 0001724521-26-000034.Report this figure33.0Revenue, Q2 FY2026, three months to 2026-06-30$33.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-05, accession 0001724521-26-000044.Report this figure
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%(1500.0%)Operating margin, Q3 FY2024, three months to 2024-09-30. operating income / revenueOperating income: −$105.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-10-28, accession 0001724521-25-000116.Revenue: $7.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-10-28, accession 0001724521-25-000116.Report this figure(447.8%)Operating margin, Q4 FY2024, three months to 2024-12-31. operating income / revenueOperating income: −$103.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-25, accession 0001724521-26-000009. Derived: 12-month figure less the 9-month figure.Revenue: $23.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-25, accession 0001724521-26-000009. Derived: 12-month figure less the 9-month figure.Report this figure(1525.0%)Operating margin, Q1 FY2025, three months to 2025-03-31. operating income / revenueOperating income: −$122.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-05, accession 0001724521-26-000034.Revenue: $8.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-05, accession 0001724521-26-000034.Report this figure(100.0%)Operating margin, Q2 FY2025, three months to 2025-06-30. operating income / revenueOperating income: −$8.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-05, accession 0001724521-26-000044.Revenue: $8.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-05, accession 0001724521-26-000044.Report this figure(2366.7%)Operating margin, Q3 FY2025, three months to 2025-09-30. operating income / revenueOperating income: −$142.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-10-28, accession 0001724521-25-000116.Revenue: $6.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-10-28, accession 0001724521-25-000116.Report this figure(1036.4%)Operating margin, Q4 FY2025, three months to 2025-12-31. operating income / revenueOperating income: −$114.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-25, accession 0001724521-26-000009. Derived: 12-month figure less the 9-month figure.Revenue: $11.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-25, accession 0001724521-26-000009. Derived: 12-month figure less the 9-month figure.Report this figure(1914.3%)Operating margin, Q1 FY2026, three months to 2026-03-31. operating income / revenueOperating income: −$134.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-05, accession 0001724521-26-000034.Revenue: $7.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-05, accession 0001724521-26-000034.Report this figure(290.9%)Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: −$96.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-05, accession 0001724521-26-000044.Revenue: $33.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-05, accession 0001724521-26-000044.Report this figure
Net margin%(1314.3%)Net margin, Q3 FY2024, three months to 2024-09-30. net income / revenueNet income: −$92.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-10-28, accession 0001724521-25-000116.Revenue: $7.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-10-28, accession 0001724521-25-000116.Report this figure(408.7%)Net margin, Q4 FY2024, three months to 2024-12-31. net income / revenueNet income: −$94.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-25, accession 0001724521-26-000009. Derived: 12-month figure less the 9-month figure.Revenue: $23.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-25, accession 0001724521-26-000009. Derived: 12-month figure less the 9-month figure.Report this figure(1400.0%)Net margin, Q1 FY2025, three months to 2025-03-31. net income / revenueNet income: −$112.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-05, accession 0001724521-26-000044.Revenue: $8.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-05, accession 0001724521-26-000034.Report this figure0.0%Net margin, Q2 FY2025, three months to 2025-06-30. net income / revenueNet income: $0. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-05, accession 0001724521-26-000044.Revenue: $8.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-05, accession 0001724521-26-000044.Report this figure(2250.0%)Net margin, Q3 FY2025, three months to 2025-09-30. net income / revenueNet income: −$135.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-10-28, accession 0001724521-25-000116.Revenue: $6.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-10-28, accession 0001724521-25-000116.Report this figure(963.6%)Net margin, Q4 FY2025, three months to 2025-12-31. net income / revenueNet income: −$106.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-25, accession 0001724521-26-000009. Derived: 12-month figure less the 9-month figure.Revenue: $11.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-25, accession 0001724521-26-000009. Derived: 12-month figure less the 9-month figure.Report this figure(1828.6%)Net margin, Q1 FY2026, three months to 2026-03-31. net income / revenueNet income: −$128.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-05, accession 0001724521-26-000044.Revenue: $7.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-05, accession 0001724521-26-000034.Report this figure(275.8%)Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: −$91.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-05, accession 0001724521-26-000044.Revenue: $33.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-05, accession 0001724521-26-000044.Report this figure
Diluted EPS$ per share(1.00)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$1.00 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-10-28, accession 0001724521-25-000116.Report this figurenot reported (Diluted EPS not reported)(1.14)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$1.14 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-05, accession 0001724521-26-000034.Report this figure0.00Diluted EPS, Q2 FY2025, three months to 2025-06-30$0.00 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-05, accession 0001724521-26-000044.Report this figure(1.27)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$1.27 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-10-28, accession 0001724521-25-000116.Report this figurenot reported (Diluted EPS not reported)(1.02)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$1.02 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-05, accession 0001724521-26-000034.Report this figure(0.72)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.72 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-05, accession 0001724521-26-000044.Report this figure
Free cash flow$m25.0Free cash flow, Q3 FY2024, three months to 2024-09-30. operating cash flow − capital expenditureOperating cash flow: $26.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-10-28, accession 0001724521-25-000116. Derived: 9-month figure less the 6-month figure.Capital expenditure: $1.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-10-28, accession 0001724521-25-000116. Derived: 9-month figure less the 6-month figure.Report this figure(101)Free cash flow, Q4 FY2024, three months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: −$100.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-25, accession 0001724521-26-000009. Derived: 12-month figure less the 9-month figure.Capital expenditure: $1.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-25, accession 0001724521-26-000009. Derived: 12-month figure less the 9-month figure.Report this figure(133)Free cash flow, Q1 FY2025, three months to 2025-03-31. operating cash flow − capital expenditureOperating cash flow: −$132.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-05, accession 0001724521-26-000034.Capital expenditure: $1.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-05, accession 0001724521-26-000034.Report this figure(133)Free cash flow, Q2 FY2025, three months to 2025-06-30. operating cash flow − capital expenditureOperating cash flow: −$133.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-05, accession 0001724521-26-000044. Derived: 6-month figure less the 3-month figure.Capital expenditure: $0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-05, accession 0001724521-26-000044. Derived: 6-month figure less the 3-month figure.Report this figure(97.0)Free cash flow, Q3 FY2025, three months to 2025-09-30. operating cash flow − capital expenditureOperating cash flow: −$97.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-10-28, accession 0001724521-25-000116. Derived: 9-month figure less the 6-month figure.Capital expenditure: $0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-10-28, accession 0001724521-25-000116. Derived: 9-month figure less the 6-month figure.Report this figure(121)Free cash flow, Q4 FY2025, three months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: −$120.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-25, accession 0001724521-26-000009. Derived: 12-month figure less the 9-month figure.Capital expenditure: $1.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-25, accession 0001724521-26-000009. Derived: 12-month figure less the 9-month figure.Report this figure(138)Free cash flow, Q1 FY2026, three months to 2026-03-31. operating cash flow − capital expenditureOperating cash flow: −$138.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-05, accession 0001724521-26-000034.Capital expenditure: $0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-05, accession 0001724521-26-000034.Report this figure(119)Free cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: −$119.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-05, accession 0001724521-26-000044. Derived: 6-month figure less the 3-month figure.Capital expenditure: $0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-05, accession 0001724521-26-000044. Derived: 6-month figure less the 3-month figure.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Last five fiscal years

Revenue$33.0mOperating margin −1169.7%
Diluted EPS−$3.29, FY2025
Free cash flow−$484.0m, FY2025
Arcus Biosciences, Inc., key figures for the last five fiscal years
Line itemUnitFY20212021-12-31FY20222022-12-31FY20232023-12-31FY20242024-12-31FY20252025-12-31Shape over the periods
Revenue$m383Revenue, FY2021, twelve months to 2021-12-31$383.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-21, accession 0001724521-24-000052.Report this figure38.0Revenue, FY2022, twelve months to 2022-12-31$38.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-02-25, accession 0001724521-25-000040.Report this figure37.0Revenue, FY2023, twelve months to 2023-12-31$37.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-25, accession 0001724521-26-000009.Report this figure51.0Revenue, FY2024, twelve months to 2024-12-31$51.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-25, accession 0001724521-26-000009.Report this figure33.0Revenue, FY2025, twelve months to 2025-12-31$33.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-25, accession 0001724521-26-000009.Report this figure
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%14.1%Operating margin, FY2021, twelve months to 2021-12-31. operating income / revenueOperating income: $54.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2024-02-21, accession 0001724521-24-000052.Revenue: $383.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-21, accession 0001724521-24-000052.Report this figure(736.8%)Operating margin, FY2022, twelve months to 2022-12-31. operating income / revenueOperating income: −$280.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-02-25, accession 0001724521-25-000040.Revenue: $38.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-02-25, accession 0001724521-25-000040.Report this figure(918.9%)Operating margin, FY2023, twelve months to 2023-12-31. operating income / revenueOperating income: −$340.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-25, accession 0001724521-26-000009.Revenue: $37.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-25, accession 0001724521-26-000009.Report this figure(647.1%)Operating margin, FY2024, twelve months to 2024-12-31. operating income / revenueOperating income: −$330.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-25, accession 0001724521-26-000009.Revenue: $51.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-25, accession 0001724521-26-000009.Report this figure(1169.7%)Operating margin, FY2025, twelve months to 2025-12-31. operating income / revenueOperating income: −$386.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-25, accession 0001724521-26-000009.Revenue: $33.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-25, accession 0001724521-26-000009.Report this figure
Net margin%13.8%Net margin, FY2021, twelve months to 2021-12-31. net income / revenueNet income: $53.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2024-02-21, accession 0001724521-24-000052.Revenue: $383.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-21, accession 0001724521-24-000052.Report this figure(702.6%)Net margin, FY2022, twelve months to 2022-12-31. net income / revenueNet income: −$267.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-02-25, accession 0001724521-25-000040.Revenue: $38.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-02-25, accession 0001724521-25-000040.Report this figure(829.7%)Net margin, FY2023, twelve months to 2023-12-31. net income / revenueNet income: −$307.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-25, accession 0001724521-26-000009.Revenue: $37.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-25, accession 0001724521-26-000009.Report this figure(554.9%)Net margin, FY2024, twelve months to 2024-12-31. net income / revenueNet income: −$283.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-25, accession 0001724521-26-000009.Revenue: $51.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-25, accession 0001724521-26-000009.Report this figure(1069.7%)Net margin, FY2025, twelve months to 2025-12-31. net income / revenueNet income: −$353.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-25, accession 0001724521-26-000009.Revenue: $33.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-25, accession 0001724521-26-000009.Report this figure
Diluted EPS$ per share0.71Diluted EPS, FY2021, twelve months to 2021-12-31$0.71 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2024-02-21, accession 0001724521-24-000052.Report this figure(3.71)Diluted EPS, FY2022, twelve months to 2022-12-31−$3.71 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-02-25, accession 0001724521-25-000040.Report this figure(4.15)Diluted EPS, FY2023, twelve months to 2023-12-31−$4.15 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-25, accession 0001724521-26-000009.Report this figure(3.14)Diluted EPS, FY2024, twelve months to 2024-12-31−$3.14 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-25, accession 0001724521-26-000009.Report this figure(3.29)Diluted EPS, FY2025, twelve months to 2025-12-31−$3.29 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-25, accession 0001724521-26-000009.Report this figure
Free cash flow$m(282)Free cash flow, FY2021, twelve months to 2021-12-31. operating cash flow − capital expenditureOperating cash flow: −$256.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2024-02-21, accession 0001724521-24-000052.Capital expenditure: $26.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2024-02-21, accession 0001724521-24-000052.Report this figure432Free cash flow, FY2022, twelve months to 2022-12-31. operating cash flow − capital expenditureOperating cash flow: $438.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-02-25, accession 0001724521-25-000040.Capital expenditure: $6.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-02-25, accession 0001724521-25-000040.Report this figure(330)Free cash flow, FY2023, twelve months to 2023-12-31. operating cash flow − capital expenditureOperating cash flow: −$306.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-25, accession 0001724521-26-000009.Capital expenditure: $24.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-25, accession 0001724521-26-000009.Report this figure(176)Free cash flow, FY2024, twelve months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: −$170.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-25, accession 0001724521-26-000009.Capital expenditure: $6.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-25, accession 0001724521-26-000009.Report this figure(484)Free cash flow, FY2025, twelve months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: −$482.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-25, accession 0001724521-26-000009.Capital expenditure: $2.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-25, accession 0001724521-26-000009.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Insider purchases and sales

All insider transactions

The last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.

By month, by reported value, last 24 monthsPurchases $15.0mSales $0
Arcus Biosciences, Inc., open-market insider transactions
DateInsiderTransactionSharesReported priceValueFiling
2025-02-18Gilead Sciences, Inc.10% owner Purchase1,363,636$11.00$15.0mForm 4
2024-01-29Gilead Sciences, Inc.10% owner Purchase15,238,095$21.00$320.0mForm 4
2023-06-28Gilead Sciences, Inc.10% owner Purchase1,010,000$19.26$19.5mForm 4
2021-01-31Gilead Sciences Inc10% owner Purchase5,650,000$39.00$220.3mForm 4

Funds that report holding it

All funds

From each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.

Funds that report holding Arcus Biosciences, Inc.
FundQuarter endedReported valueSharesPut or callChange on the quarter before
GILEAD SCIENCES, INC.2026-06-30$968.8m31,424,760Unchanged
BlackRock, Inc.2026-06-30$506.1m16,416,249Added+1,189,774
STATE STREET CORP2026-06-30$185.9m6,029,484Added+616,583
WELLINGTON MANAGEMENT GROUP LLP2026-06-30$181.8m5,895,448Reduced−194,068
MONTANOVA CAPITAL, LLC2026-06-30$147.3m4,776,423Reduced−254,570
VANGUARD PORTFOLIO MANAGEMENT LLC2026-06-30$138.0m4,475,528Added+203,472
FMR LLC2026-06-30$124.9m4,049,757Added+2,884,505
VANGUARD CAPITAL MANAGEMENT LLC2026-06-30$119.9m3,888,346Added+31,621
CITADEL ADVISORS LLC2026-06-30$96.7m3,135,057Added+1,805,122
Woodline Partners LP2026-06-30$92.7m3,007,798Reduced−770,000

Recent filings

All 587 filings

Reports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.

Arcus Biosciences, Inc., recent filings
FiledFormWhat it isAccession number
2026-10-2320:12 ET8-K8.01 Other events; 9.01 Financial statements and exhibits0001724521-26-000050
2026-10-2120:09 ET8-K2.02 Results of operations0001193125-26-427829
2026-10-2012:33 ET8-K8.01 Other events0001724521-26-000047
2026-08-0520:11 ET10-QQuarterly reportPeriod 2026-06-300001724521-26-000044
2026-08-0520:07 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001724521-26-000042
2026-06-1220:12 ET8-K5.07 Shareholder vote results0001724521-26-000037
2026-05-0520:11 ET10-QQuarterly reportPeriod 2026-03-310001724521-26-000034
2026-05-0520:09 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001724521-26-000032
2026-04-2120:06 ETDEF 14AProxy statementPeriod 2026-06-110001724521-26-000025
2026-04-2011:56 ET8-K8.01 Other events0001724521-26-000021

Latest annual report

Form 10-K for the fiscal year ended Dec 31, 2025Filed Feb 25, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.

Forecast league

Not in this season’s league. The league lists companies whose quarter has ended and whose results are not yet filed.This season’s league

About the filer

CIK
1724521
Tickers
RCUS
Exchange
NYSE
SIC code
2834 Pharmaceutical Preparations
Sector
Healthcare
Fiscal year ends
Dec 31
Incorporated in
DE
Filer category
Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:46 ET. Listed shows no prices and gives no investment advice.